Compass Therapeutics (CMPX) News Today $2.73 -0.17 (-5.86%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$2.79 +0.06 (+2.20%) As of 03/3/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Q1 Earnings Estimate for CMPX Issued By HC WainwrightMarch 4 at 2:09 AM | americanbankingnews.comResearch Analysts Issue Forecasts for CMPX Q1 EarningsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Compass Therapeutics in a report released on Thursday, February 27th. HC Wainwright analyst J. Pantginis anticipates that the company will poMarch 3 at 2:08 AM | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSCompass Therapeutics (NASDAQ:CMPX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01).February 28, 2025 | marketbeat.comCompass Therapeutics shares rise on pipeline progressFebruary 28, 2025 | za.investing.comCompass Therapeutics reports Q4 EPS (11c), consensus (9c)February 28, 2025 | markets.businessinsider.comCompass Therapeutics sees cash runway into 1Q27February 28, 2025 | markets.businessinsider.comCritical Analysis: Compass Therapeutics (NASDAQ:CMPX) vs. Replimune Group (NASDAQ:REPL)February 28, 2025 | americanbankingnews.comCompass Therapeutics Reports 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | globenewswire.comD. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX)February 27, 2025 | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at GuggenheimFebruary 26, 2025 | americanbankingnews.comCompass Therapeutics' (CMPX) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday.February 25, 2025 | marketbeat.comGuggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy RecommendationFebruary 25, 2025 | msn.comCompass Therapeutics initiated with a Buy at GuggenheimFebruary 24, 2025 | markets.businessinsider.comCompass Therapeutics (NASDAQ:CMPX) Coverage Initiated at GuggenheimGuggenheim initiated coverage on shares of Compass Therapeutics in a research note on Monday. They set a "buy" rating and a $12.00 price objective on the stock.February 24, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Compass Therapeutics (CMPX) with Overweight RecommendationFebruary 20, 2025 | msn.comPiper Sandler Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday. They issued an "overweight" rating and a $12.00 price target for the company.February 20, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest UpdateCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,750,000 shares, a decrease of 13.8% from the January 15th total of 3,190,000 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average trading volume of 1,280,000 shares, the days-to-cover ratio is presently 2.1 days.February 17, 2025 | marketbeat.comTwo new option listings on February 11thFebruary 12, 2025 | markets.businessinsider.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Down 7.6% - Here's WhyCompass Therapeutics (NASDAQ:CMPX) Stock Price Down 7.6% - Time to Sell?February 11, 2025 | marketbeat.comCompass Therapeutics price target raised to $8 from $7 at JefferiesFebruary 11, 2025 | markets.businessinsider.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have given aFebruary 11, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, Jefferies Financial Group Analyst SaysJefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday.February 10, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High - Time to Buy?Compass Therapeutics (NASDAQ:CMPX) Hits New 1-Year High - Still a Buy?February 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for CMPX FY2024 Earnings?Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities researchers at Leerink Partnrs raised their FY2024 earnings estimates for shares of Compass Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the company will poFebruary 10, 2025 | marketbeat.comWhy Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025February 4, 2025 | msn.comTop 3 High-Momentum Companies Analysts Are Still Bullish OnMomentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.February 4, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by SG Americas Securities LLCSG Americas Securities LLC raised its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 921.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 395,017 shares of the company's sFebruary 1, 2025 | marketbeat.comCompass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | markets.businessinsider.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Barclays PLCBarclays PLC increased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 195.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,245 shares of the company's stock after purchasing aJanuary 20, 2025 | marketbeat.comShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 5.2%Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 15th total of 2,100,000 shares. Currently, 2.6% of the company's stock are short sold. Based on an average daily volume of 875,000 shares, the days-to-cover ratio is presently 2.5 days.January 19, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from AnalystsCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on theJanuary 17, 2025 | marketbeat.comCompass Therapeutics stock hits 52-week high at $2.68January 16, 2025 | msn.comCompass Therapeutics: Strategic Advancements and Promising Pipeline Justify Buy RatingJanuary 9, 2025 | markets.businessinsider.comCompass Therapeutics: Strong Growth Potential Bolstered by Upcoming Milestones and Strategic FocusJanuary 8, 2025 | markets.businessinsider.comAnother Day, Another Biotech Stealing The ShowJanuary 8, 2025 | msn.comCompass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug CandidateJanuary 8, 2025 | finance.yahoo.comCompass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday.January 8, 2025 | marketbeat.comCompass Therapeutics initiated with a Buy at D. Boral CapitalDecember 24, 2024 | markets.businessinsider.comD. Boral Capital Initiates Coverage of Compass Therapeutics (CMPX) with Buy RecommendationDecember 24, 2024 | msn.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Moderate Buy" by AnalystsCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have assigDecember 23, 2024 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Coverage Initiated at D. Boral CapitalD. Boral Capital began coverage on Compass Therapeutics in a research note on Monday. They issued a "buy" rating and a $32.00 price objective on the stock.December 23, 2024 | marketbeat.comJanus Henderson Group PLC Has $3.36 Million Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX)Janus Henderson Group PLC decreased its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 64.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,843,286 shares of the company's stock aDecember 12, 2024 | marketbeat.comCompass Therapeutics Appoints New CFO Amid Strategic MovesDecember 11, 2024 | markets.businessinsider.comCompass Therapeutics Names Barry Shin Chief Financial OfficerDecember 10, 2024 | marketwatch.comCompass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerDecember 10, 2024 | markets.businessinsider.comCompass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerDecember 10, 2024 | globenewswire.comCompass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary CancerDecember 9, 2024 | seekingalpha.comCompass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceDecember 2, 2024 | globenewswire.comCompass Therapeutics (NASDAQ:CMPX) Downgraded to "Hold" Rating by Leerink PartnrsLeerink Partnrs cut shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday.November 16, 2024 | marketbeat.comCompass downgrade ‘curious,’ presents upside, says H.C. WainwrightNovember 15, 2024 | markets.businessinsider.com Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Media Mentions By Week CMPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.190.70▲Average Medical News Sentiment CMPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼182▲CMPX Articles Average Week Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IOVA News TVTX News IRON News NAMS News WVE News EVO News SDGR News AMPH News APGE News IMCR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
